Related Experiment Video
Updated: Jul 2, 2026
08:40
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Dendritic cell maturation with CpG for tumor immunotherapy
Samaneh Arab1, Masoumeh Motamedi, Nematollah Khansari
1Department of Immunology, Medical School, Tehran University of Medical Sciences, Tehran, Iran.
Iranian Journal of Immunology : IJI
|August 14, 2008
Summary
CpG-1826 matured dendritic cells (DCs) enhanced anti-tumor immunity in a mouse model. This immunotherapy approach significantly boosted cytotoxic T cell activity and reduced tumor growth, showing promise for cancer treatment strategies.
Area of Science:
- Immunology
- Cancer Research
- Cellular Therapy
Background:
- Bacterial DNA, specifically CpG-1826, exhibits immunostimulatory properties.
- Dendritic cells (DCs) are key immune cells that can be utilized as cellular adjuvants.
- DCs hold potential for immunotherapy against infectious diseases and cancers.
Purpose of the Study:
- To evaluate the efficacy of tumor antigen-pulsed DCs combined with CpG-1826 in a murine cancer model.
- To investigate the impact of this combined immunotherapy on tumor growth and immune response.
Main Methods:
- WEHI-164 fibrosarcoma cells were used to establish tumors in mice.
- Bone marrow-derived DCs were cultured and matured with tumor lysate and CpG-1826.
- DCs were administered around the tumor site, and tumor growth was monitored.
- Splenic T cell cytotoxicity against tumor cells was assessed.
Main Results:
- Immunotherapy with CpG-1826 treated DCs significantly increased cytotoxic T cell activity.
- A notable decrease in tumor growth was observed in mice treated with CpG-1826 matured DCs.
- Control groups receiving DCs without CpG treatment showed no significant changes.
Conclusions:
- DCs matured with CpG-1826 can effectively induce specific anti-tumor immune responses.
- CpG-1826 holds potential for use in DC-targeted clinical cancer immunotherapy strategies.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...